Research programme: anti-infectives - Oscient Pharmaceuticals
Alternative Names: GTC 162 series; GTC 637 seriesLatest Information Update: 17 Jan 2011
At a glance
- Originator Oscient Pharmaceuticals
- Class
- Mechanism of Action Peptide deformylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Respiratory tract infections
Most Recent Events
- 25 Oct 2007 This programme is still in active development
- 29 Sep 2005 Oscient's oral PDF inhibitors research programme is available for licensing (http://www.oscient.com)
- 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals